Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cholera drug could cut antibiotic use and hospital stays

NCT ID NCT06193408

Disease control Sponsor: Hunazine Biotech S.L. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called VR-AD-1005 for treating severe diarrhea caused by cholera. The drug aims to reduce fluid loss and the need for antibiotics, which could help fight antibiotic resistance. 150 adults with cholera took part, and researchers measured stool output and rehydration needs compared to a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

150 people

The number who actually took part.

Started

Feb 2024

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent. * Adults, both genders aged 18-65 years. * Acute watery diarrhea (defined as passage of three or more liquid stools within the 24 hours before admission) with severe dehydration on arrival. * Detection of V. cholerae by rapid diagnostic assay (e.g. dark field microscopy). Exclusion Criteria: * Known or suspected hypersensitivity to trial product(s) or related products. * Subjects with passage of bloody stools or muco-purulent stools. * Subjects with chronic diarrhea (\>4 weeks of Diarrhea). * Clinically significant concomitant systemic disease (i.e. cardiovascular diseases including heart failure, acute kidney injury, sepsis or life-threatening malignant cancer). * Mental incapacity, unwillingness, or language barriers, precluding adequate understanding or cooperation. * History of receiving antimicrobial or antidiarrheal drugs within 6 hours prior to admission. * Positive urine pregnancy test for all female patients * Failure to obtain informed consent. * Failure to definitively diagnose cholera via culture or RT-PCR

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cholera are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cholera

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cholera

Contacts and locations

Locations

  • Icddr,b

    Dhaka, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.